Orna Therapeutics is a Cambridge, Massachusetts biotechnology company, founded in 2019 on research from MIT and built by MPM Capital, that engineers circular RNA (oRNA) paired with lipid nanoparticle delivery so a patient's own body generates cell therapies — its lead program ORN-252 is a CD19-targeting in vivo CAR-T designed for B-cell-driven autoimmune disease. Orna acquired ReNAgade Therapeutics in 2024, combining its circular RNA platform with ReNAgade's LNP delivery and RNA editing capabilities, and Eli Lilly announced a definitive agreement to acquire Orna on 2026-02-09 for up to $2.4B. Orna is a therapeutics developer, not a software vendor: it publishes no API, developer portal, SDK or machine-readable contract, and as of this profile its own domain ornatx.com redirects in whole to Eli Lilly's subsidiaries page.
Orna Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Therapeutics, RNA, and Life Sciences.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
aid: orna-therapeutics
name: Orna Therapeutics
description: 'Orna Therapeutics is a Cambridge, Massachusetts biotechnology company, founded in 2019 on research from MIT
and built by MPM Capital, that engineers circular RNA (oRNA) paired with lipid nanoparticle delivery so a patient''s own
body generates cell therapies — its lead program ORN-252 is a CD19-targeting in vivo CAR-T designed for B-cell-driven autoimmune
disease. Orna acquired ReNAgade Therapeutics in 2024, combining its circular RNA platform with ReNAgade''s LNP delivery
and RNA editing capabilities, and Eli Lilly announced a definitive agreement to acquire Orna on 2026-02-09 for up to $2.4B.
Orna is a therapeutics developer, not a software vendor: it publishes no API, developer portal, SDK or machine-readable
contract, and as of this profile its own domain ornatx.com redirects in whole to Eli Lilly''s subsidiaries page.'
url: https://raw.githubusercontent.com/api-evangelist/orna-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
deliveryModel:
model: unknown
open_source: false
commercial: false
callable_host: false
label: Delivery model not determined — needs a product licence on record
confidence: low
source:
- none
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source:
- security
- url: https://www.ornatx.com/
status: 301
note: declared website redirects to https://www.lilly.com/science/subsidiaries — a different registrable domain (ornatx.com
-> lilly.com), possible rename or acquisition (probed 2026-09-03, roadmap#169)
generated: '2026-09-02'
method: derived
specificationVersion: '0.20'
created: '2026-08-26'
modified: '2026-08-26'
tags:
- Company
- Biotechnology
- Therapeutics
- RNA
- Life Sciences
- Pharmaceuticals
- Cell Therapy
- Research
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: DomainSecurity
url: security/orna-therapeutics-domain-security.yml
- type: Website
url: https://www.ornatx.com/
- type: GitHubOrganization
url: https://github.com/OrnaComputationTeam
- type: ParentCompany
url: https://www.lilly.com/science/subsidiaries
- type: LinkedIn
url: https://www.linkedin.com/company/ornatx
x-enrichment:
date: '2026-08-26'
status: minimal
artifacts_added: 2
pass: local-v1
x-coverage:
state: none
reason: defunct
detail: Orna Therapeutics is a clinical-stage RNA therapeutics developer with no software product, and since Eli Lilly's
acquisition (definitive agreement announced 2026-02-09) its entire domain ornatx.com answers HTTP 301 to https://lilly.com/science/subsidiaries
— every /.well-known/* path included — so the only surface it still operates is a GitHub org of 44 forked third-party
RNA structure-prediction tools and one internal CodeCommit sync action, none of which is an API.
evidence:
- url: https://www.ornatx.com/
status: 301
- url: https://www.ornatx.com/.well-known/api-catalog
status: 301
- url: https://www.ornatx.com/openapi.json
status: 404
- url: https://www.ornatx.com/llms.txt
status: 404
- url: https://github.com/OrnaComputationTeam
status: 200
checked: '2026-08-26'
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.
Kin Score
How this is scored →